DBV Technologies (NASDAQ:DBVT) Shares Pass Above 50 Day Moving Average – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT) shares crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $8.89 and traded as high as $9.62. DBV Technologies shares last traded at $9.10, with a volume of 13,611 shares traded.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. JMP Securities boosted their price objective on shares of DBV Technologies from $15.00 to $21.00 and gave the company a “market outperform” rating in a report on Tuesday, May 27th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, May 9th. HC Wainwright lifted their price objective on DBV Technologies from $7.00 to $16.00 and gave the company a “buy” rating in a report on Monday, May 5th. The Goldman Sachs Group upgraded DBV Technologies to a “sell” rating and set a $7.25 target price for the company in a research report on Thursday, May 29th. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $14.75.

DBV Technologies Trading Down 6.1%

The firm’s 50-day moving average is $8.89 and its 200 day moving average is $5.90. The firm has a market capitalization of $249.25 million, a price-to-earnings ratio of -2.02 and a beta of -0.63.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The firm had revenue of $0.51 million for the quarter. Analysts predict that DBV Technologies S.A. will post -7.05 EPS for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.